Document is current

Article History

Received: 29 May 2018

Accepted: 13 July 2018

First Online: 25 July 2018

Ethics approval and consent to participate

: The KHSS was approved by Institutional Review Board of Hallym University Sacred Heart Hospital (approval No. 2011-I077). We received written consent from all participants before survey interview.

: Not applicable.

: Tae-Jin Song has no potential conflicts of interest.Soo-Jin Cho was a site investigator of multicenter trial sponsored by Otsuka Korea, Eli Lilly and Company, Korea BMS, and Parexel Korea Co., Ltd.. Soo-Jin Cho also worked as an advisory member for Teva. Soo-Jin Cho received research support from Hallym University Research Fund 2016 and Academic award of Myung In Pharm. Co. Ltd. Soo-Jin Cho also received lecture honoraria from Yuyu Pharmaceutical Company and Allergan Korea.Won-Joo Kim has no potential conflicts of interest.Kwang Ik Yang has no potential conflicts of interest.Chang-Ho Yun has no potential conflicts of interest.Min Kyung Chu was a site investigator for a multi-center trial sponsored by Eli Lilly and company; worked an advisory member for Teva, and received lecture honoraria from Allergan Korea and Yuyu Pharmaceutical Company in the past 24 months. The authors declare that they have no competing interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.